Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Novartis Invested in an R&D Facility in Shanghai, Despite Challenges

By Meg Snyder | June 2, 2016

Novartis’ Shanghai R&D facility, a $1 billion research center that has been in the works since 2009, officially opened its doors this week. Novartis also has two other R&D centers, which are located in Cambridge, Mass., and Basel, Switzerland.

Ten years ago, many companies were drawn to China on account of lower salaries among their scientists. Today, however, companies are tasked with a challenge in the Chinese pharmaceutical market: government pressure on drug prices.

According to an article in the Asset magazine, “[i]n China, prescriptions drugs drive around 40% of total healthcare spending compared to 15% in the U.S., so the government has preferred generics to cut costs.”

Keep in mind that this is in addition to scandals, such as GSK’s bribery case, and regulatory hurdles, like slow registration processes for new drugs.

Despite these apparent challenges, Novartis CEO, Joe Jimenez, “is keen to look past recent troubles for the industry in the region, saying that there has ‘been an explosion of talent in China,’” according to a report in Fierce Biotech. This declaration comes soon after monumental changes within the company, as Novartis recently split its drug division in two: Novartis Oncology and Novartis Pharmaceuticals. 

“The Chinese historically have not been proven innovators in certain areas [drug discovery],” Jimenez told Fortune. “If you look at what’s happening now, it’s changing. I think partly because of the flood of new technologies that are emerging, and companies like Novartis that are training Chinese scientists in the way that we discover drugs.”

According to an interview Jimenez had with Fortune, the company is currently spending about $200 billion each year on research and development, which is second only to the U.S.

“Single-digit growth is going to be the new normal in China,” Jimenez said. “We had consistently seen 11% or 12% growth five or six years ago. The economic slowdown has led to a slowing because a lot of pharmaceuticals in China are still paid out-of-pocket. But we’re saying look, when you compare to U.S.’s 1% to 2% growth or Europe’s 1%, it’s pretty good.”

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE